Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Bologna |
---|---|
Information provided by: | University of Bologna |
ClinicalTrials.gov Identifier: | NCT00799799 |
AML patients with de-novo or secondary disease with age greater than 18 years not eligible for stem cell transplantation for medical contraindications, lack of donor or lack of stem cells,are eligible. Leukemias other than AML and M3 FAB subtype will be excluded from the study. Immunosuppressive chemotherapy prior to NK cell infusion will include: fludarabine and cyclophosphamide 4g/m2 (Flu/Cy). The therapy will be administered over 6 days on inpatient basis. Haploidentical NK cells will be selected from a steady-state large volume leukapheresis product from a suitable KIR ligand incompatible donor. Donor-recipients pairs will be selected on the basis of known KIR ligands. In particular, haploidentical donors will be included if present at least one allele mismatch at a class I locus among the following ones: HLA-C alleles with Asn77-Lys80, HLA-C alleles with Ser77-Asn80, HLA-Bw4 alleles. Immunomagnetic enrichment of NK cells will follow two subsequent steps: 1) depletion of CD3+ T cells followed by 2) positive selection of CD56+ NK cells. Contaminating CD3+ T cells will be carefully evaluated.
Condition | Intervention | Phase |
---|---|---|
Myeloblastic Leukemia |
Biological: NK cells |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Historical Control, Single Group Assignment, Safety Study |
Official Title: | Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-Mismatched Natural Killer Cells |
Estimated Enrollment: | 15 |
Study Start Date: | October 2005 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
NK: Experimental
patient treated as per protocol
|
Biological: NK cells
NK cells infusion after immunosuppressive chemotherapy
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Roberto M Lemoli, MD | +39 051 636 ext 3680 | roberto.lemoli@unibo.it |
Contact: Antonio Curti, MD | +39 051 636 ext 3680 | antonio.curti2@unibo.it |
Italy, Bo | |
Institute of Hematology "L. & A. Seragnoli" | Recruiting |
Bologna, Bo, Italy, 40138 |
Responsible Party: | Institute of Hematology "L. & A. Seragnoli" - University of Bologna ( prof. Roberto M. Lemoli ) |
Study ID Numbers: | NK TRIAL |
Study First Received: | November 28, 2008 |
Last Updated: | December 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00799799 |
Health Authority: | Italy: Ethics Committee |
Nk cells infusion minimal residual disease in AML patients trafficking of NK cells after infusion cytolytic effects on leukemic cells |
Neoplasm, Residual Leukemia Acute myelogenous leukemia |
Leukemia, Myeloid Leukemia, Myeloid, Acute Acute myelocytic leukemia |
Neoplasms Neoplasms by Histologic Type |